Access the full text.
Sign up today, get DeepDyve free for 14 days.
Van Wyck (2009)
Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.Transfusion, 49
Anthony Lopez, P. Cacoub, I. Macdougall, L. Peyrin-Biroulet (2016)
Iron deficiency anaemiaThe Lancet, 387
R. Derman, E. Roman, M. Modiano, M. Achebe, L. Thomsen, M. Auerbach (2017)
A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemiaAmerican Journal of Hematology, 92
T. Shimada, H. Hasegawa, Y. Yamazaki, T. Muto, Rieko Hino, Y. Takeuchi, T. Fujita, K. Nakahara, S. Fukumoto, T. Yamashita (2003)
FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 19
M. Auerbach, Lars Lykke (2018)
A Single Infusion of Iron Isomaltoside 1000 Allows a More Rapid Hemoglobin Increment Than Multiple Doses of Iron Sucrose with a Similar Safety Profile in Patients with Iron Deficiency AnemiaBlood
T. Urbina, R. Belkhir, Geoffrey Rossi, F. Carbonnel, S. Pavy, M. Collins, X. Mariette, R. Seror (2018)
Iron Supplementation–Induced Phosphaturic Osteomalacia: FGF23 is the CulpritJournal of Bone and Mineral Research, 33
Xin Yan, Xiaogang Su (2010)
Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial ProportionsStatistics in Biopharmaceutical Research, 2
P. Burckhardt (2018)
Im eigenen Fachgebiet auf dem Laufenden bleibenOsteologie, 27
Klara Klein, Shonda Asaad, M. Econs, J. Rubin (2018)
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administrationBMJ Case Reports, 2018
Y. Nagata, Y. Imanishi, Akira Ishii, M. Kurajoh, K. Motoyama, T. Morioka, H. Naka, K. Mori, T. Miki, M. Emoto, M. Inaba (2011)
Evaluation of bone markers in hypophosphatemic rickets/osteomalaciaEndocrine, 40
D. Girelli, S. Ugolini, F. Busti, G. Marchi, A. Castagna (2017)
Modern iron replacement therapy: clinical and pathophysiological insightsInternational Journal of Hematology, 107
G. Birgegard, D. Henry, J. Glaspy, R. Chopra, L. Thomsen, M. Auerbach (2016)
A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND TrialPharmacotherapy, 36
M. Wolf, G. Chertow, I. Macdougall, R. Kaper, J. Krop, W. Strauss (2018)
Randomized trial of intravenous iron-induced hypophosphatemia.JCI insight, 3 23
C. Camaschella (2015)
Iron-deficiency anemia.The New England journal of medicine, 372 19
H. Peach, J. Compston, S. Vedi, L. Horton (1982)
Value of plasma calcium, phosphate, and alkaline phosphatase measurements in the diagnosis of histological osteomalaciaJournal of Clinical Pathology, 35
L. Quarles, J. Clin, Yanfeng Wang, R. Litvinov, Xinsheng Chen, Tami Bach, L. Lian, B. Petrich, S. Monkley, Y. Kanaho, D. Critchley, Takehiko Sasaki, M. Birnbaum, J. Weisel, J. Hartwig, C. Abrams (2008)
Endocrine functions of bone in mineral metabolism regulation.The Journal of clinical investigation, 118 12
J. Potts (2005)
Parathyroid hormone: past and present.The Journal of endocrinology, 187 3
I. Emrich, Fabio Lizzi, Seiler-Mußler Sarah, C. Ukena, D. Kaddu-Mulindwa, M. Böhm, S. Stilgenbauer, D. Fliser, V. Brandenburg, G. Heine (2018)
Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) — the Randomised Controlled Home Afers 1 TrialBlood
J. Dahlerup, B. Jacobsen, J. Woude, L. Bark, L. Thomsen, S. Lindgren (2016)
High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23Scandinavian Journal of Gastroenterology, 51
D. Wyck, A. Mangione, J. Morrison, Phillip Hadley, Judi Jehle, L. Goodnough (2009)
BLOOD MANAGEMENT: Large‐dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trialTransfusion, 49
H. Reichel, H. Koeffler, A. Norman (1989)
The role of the vitamin D endocrine system in health and disease.The New England journal of medicine, 320 15
M. Wolf, Todd Koch, D. Bregman (2013)
Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in womenJournal of Bone and Mineral Research, 28
M. Holick (2007)
Vitamin D deficiency.The New England journal of medicine, 357 3
T. Detlie, J. Lindstrøm, M. Jahnsen, E. Finnes, H. Zoller, B. Moum, J. Jahnsen (2019)
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltosideAlimentary Pharmacology & Therapeutics, 50
R. Subramanian, R. Khardori (2000)
Severe Hypophosphatemia: Pathophysiologic Implications, Clinical Presentations, and TreatmentMedicine, 79
Burckhardt (2018)
Iron-induced osteomalacia.Osteologie, 27
S. Bhandari, Dora Pereira, H. Chappell, H. Drakesmith (2018)
Intravenous Irons: From Basic Science to Clinical PracticePharmaceuticals, 11
C. Holm, L. Thomsen, A. Nørgaard, J. Langhoff‐Roos (2017)
Single‐dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trialVox Sanguinis, 112
W. Reinisch, M. Staun, R. Tandon, I. Altorjay, A. Thillainayagam, C. Gratzer, S. Nijhawan, L. Thomsen (2013)
A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)The American Journal of Gastroenterology, 108
J. Onken, D. Bregman, R. Harrington, David Morris, P. Ács, Bruce Akright, C. Barish, Birbal Bhaskar, Gioi Smith‐Nguyen, A. Butcher, Todd Koch, L. Goodnough (2013)
A multicenter, randomized, active‐controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemiaTransfusion, 54
E. Farrow, Xijie Yu, Lelia Summers, S. Davis, J. Fleet, M. Allen, A. Robling, K. Stayrook, V. Jideonwo, Martin Magers, H. Garringer, R. Vidal, R. Chan, Charles Goodwin, S. Hui, M. Peacock, K. White (2011)
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in miceProceedings of the National Academy of Sciences, 108
B. Schaefer, B. Glodny, H. Zoller (2017)
Blood and Bone Loser.Gastroenterology, 152 6
B. Favrat, K. Balck, C. Breymann, M. Hedenus, T. Keller, A. Mezzacasa, C. Gasche (2014)
Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women – PREFER a Randomized, Placebo-Controlled StudyPLoS ONE, 9
J. Onken, D. Bregman, R. Harrington, David Morris, J. Buerkert, D. Hamerski, H. Iftikhar, R. Mangoo‐Karim, E. Martin, Carlos Martinez, George Newman, W. Qunibi, D. Ross, Bhupinder Singh, Mark Smith, A. Butcher, Todd Koch, L. Goodnough (2014)
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29 4
Daniel Edmonston, M. Wolf (2019)
FGF23 at the crossroads of phosphate, iron economy and erythropoiesisNature Reviews Nephrology, 16
P. Burckhardt (2018)
Eisen-induzierte OsteomalazieOsteologie, 27
Farrow (2011)
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.Proc Natl Acad Sci U S A, 108
H. Zoller, B. Schaefer, B. Glodny (2017)
Iron-induced hypophosphatemia: an emerging complicationCurrent Opinion in Nephrology and Hypertension, 26
Key PointsQuestionWhat are the risks of hypophosphatemia following iron replacement with iron isomaltoside 1000 (now called ferric derisomaltose) vs ferric carboxymaltose? FindingsIn 2 randomized trials of 245 total patients (trial A: n = 123; trial B: n = 122) with iron-deficiency anemia, who were intolerant to or unresponsive to oral iron, the incidence of hypophosphatemia with use of iron isomaltoside, compared with ferric carboxymaltose, was 7.9% vs 75.0% in trial A and 8.1% vs 73.7% in trial B over 35 days; both differences were statistically significant. MeaningIron isomaltoside, compared with ferric carboxymaltose, resulted in lower incidence of hypophosphatemia, but further research is needed to determine the clinical importance of these findings.
JAMA – American Medical Association
Published: Feb 4, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.